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A comparison of the predictive accuracy of three
screening models for pulmonary arterial
hypertension in systemic sclerosis
Yanjie Hao1,2, Vivek Thakkar1,3,4, Wendy Stevens1, Kathleen Morrisroe1, David Prior5, Candice Rabusa1,
Peter Youssef6, Eli Gabbay7, Janet Roddy8, Jennifer Walker9, Jane Zochling10, Joanne Sahhar11, Peter Nash12,
Susan Lester13, Maureen Rischmueller13,15, Susanna M Proudman14,15 and Mandana Nikpour1,16*

Abstract
Introduction: There is evidence that early screening for pulmonary arterial hypertension (PAH) in systemic sclerosis
(SSc) improves outcomes. We compared the predictive accuracy of two recently published screening algorithms
(DETECT 2013 and Australian Scleroderma Interest Group (ASIG) 2012) for SSc-associated PAH (SSc-PAH) with the
commonly used European Society of Cardiology/European Respiratory Society (ESC/ERS 2009) guidelines.
Methods: We included 73 consecutive SSc patients with suspected PAH undergoing right heart catheterization
(RHC). The three screening models were applied to each patient. For each model, contingency table analysis was
used to determine sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values for PAH. These
properties were also evaluated in an ‘alternate scenario analysis’ in which the prevalence of PAH was set at 10%.
Results: RHC revealed PAH in 27 (36.9%) patients. DETECT and ASIG algorithms performed equally in predicting
PAH with sensitivity and NPV of 100%. The ESC/ERS guidelines had sensitivity of 96.3% and NPV of only 91%,
missing one case of PAH; these guidelines could not be applied to three patients who had absent tricuspid
regurgitant (TR) jet. The ASIG algorithm had the highest specificity (54.5%). With PAH prevalence set at 10%, the
NPV of the models was unchanged, but the PPV dropped to less than 20%.
Conclusions: In this cohort, the DETECT and ASIG algorithms out-perform the ESC/ERS guidelines, detecting all
patients with PAH. The ESC/ERS guidelines have limitations in the absence of a TR jet. Ultimately, the choice of
SSc-PAH screening algorithm will also depend on cost and ease of application.

Introduction
Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by vasculopathy and fibrosis.
Pulmonary arterial hypertension (PAH) is one of the
most severe organ complications and a leading cause of
death in SSc. Despite advanced PAH therapies, the 3-year
survival of SSc-associated PAH (SSc-PAH) is around 50%
[1]. Recent evidence indicates that the earlier treatment is
started in the course of disease, the better the prognosis
[2-4]. Therefore, early detection of PAH has become an
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important consideration in the optimal management of patients with SSc.
The most commonly used pulmonary hypertension
screening guidelines from the European Society of
Cardiology/European Respiratory Society (ESC/ERS) are
based on symptoms and transthoracic echocardiography
(TTE) [5]. But there are limitations in symptom- and
TTE-based algorithms. In the early stages, the symptoms
of PAH are usually very mild and non-specific, making it
difficult to identify patients who are developing PAH. In
patients with SSc, coexisting organ involvement such as
interstitial lung disease (ILD) makes the diagnosis of PAH
even more challenging. In addition, the most widely used
echocardiographic parameter, tricuspid regurgitant jet velocity (TRV), is not present in all patients. In fact, TRV
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cannot be obtained in 20% to 39% of patients, potentially
decreasing the sensitivity of TTE-based algorithms [6,7].
Another consideration is the cost-effectiveness of TTEbased screening.
These limitations of current screening algorithms
emphasize the need for alternative approaches to improve the selection of patients for referral for right heart
catheterization (RHC), the ‘gold standard’ test for the diagnosis of PAH. Emerging screening algorithms incorporate
pulmonary function tests (PFTs) and biomarkers such as
N-terminal pro-B type natriuretic peptide (NT-proBNP)
[8-12]. In 2012, the Australian Scleroderma Interest Group
(ASIG) developed a screening algorithm for SSc-PAH by
using serum NT-proBNP level and PFT [11]; this was
found to have similar sensitivity and higher specificity and
positive (PPV) and negative (NPV) predictive value in
comparison with the ESC/ERS guidelines [13].
The DETECT (Evidence-Based Detection of Pulmonary
Arterial Hypertension in Systemic Sclerosis) study investigators recently developed a new detection algorithm for
PAH in patients with SSc [14]. This study included 644 patients with diffusing capacity for carbon monoxide (DLCO)
of less than 60% predicted, from 18 countries in North
America, Europe, and Asia. The algorithm combined eight
variables—telangiectasia, anti-centromere antibody (ACA),
NT-proBNP, serum urate, forced vital capacity (FVC) percentage predicted/DLCO percentage predicted (FVC/
DLCO) on PFT, right axis deviation on electrocardiogram
(ECG), right atrium (RA) area, and TRV on TTE—and
established a two-step decision tree, which improved the
sensitivity of screening for SSc-PAH from 71% to 96% in
comparison with the ESC/ERS guidelines. However, to
date, the performance of the DETECT algorithm has not
been evaluated among patients who were not included in
the derivation study. Therefore, the aims of this study
were to validate the predictive accuracy of the DETECT
algorithm in Australian patients with SSc and to compare
the performances of DETECT and ASIG algorithms with
the ESC/ERS guidelines.

Methods
Patients

Patients included in this analysis were from the Australian
Scleroderma Cohort Study (ASCS). The ASCS is a multicenter study of risk and prognostic factors for cardiopulmonary outcomes in SSc. All patients fulfil either
American College of Rheumatology or Leroy and Medsger
criteria for SSc [15,16]. The ASCS has been approved
by the human research ethics committees of the 13
participating Australian centers (St Vincent’s Hospital
Melbourne, Royal Perth Hospital, Royal Adelaide Hospital,
The Queen Elizabeth Hospital, Sunshine Coast Rheumatology, Prince Charles Hospital, John Hunter Hospital,
Royal Prince Alfred Hospital, Royal North Shore Hospital,
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St George Hospital, Canberra Rheumatology, Monash
Medical Centre, and The Menzies Research Institute
Tasmania). All patients provide written informed consent
at recruitment.
Inclusion and exclusion criteria

We included consecutive adult (≥18 years) SSc patients
from the ASCS between December 2007 and December
2012, who were considered to be at high risk for PAH according to the ASCS screening guidelines and had undergone RHC. The existing Australian screening guidelines
require that all patients undergo an annual clinical assessment, TTE and PFTs. Any patient identified as having possible PAH—that is, systolic pulmonary arterial pressure
(sPAPTTE) of at least 40 mm Hg, and/or DLCO less than
50% predicted with FVC of more than 85% predicted,
without adequate explanation on high-resolution computed tomography (HRCT) lung or ventilation-perfusion
(V/Q) scanning or both—undergoes RHC.
In addition to undergoing RHC, all patients have serum
collected for NT-proBNP measurement within 1 month of
their RHC and, in cases of PAH, prior to the commencement of advanced pulmonary vasodilator therapy.
In keeping with the exclusion criteria of the DETECT
study [14], patients were excluded if they had pulmonary
hypertension (PH) confirmed by RHC prior to enrolment, were receiving advanced PH therapy, had an FVC
of less than 40% of predicted or renal insufficiency, or
were pregnant. As per the DETECT algorithm, patients
with more than one missing variable among eight variables were also excluded.
For validating the performance of the ESC/ERS guidelines, patients without detectable TRV were excluded.
For validating the performance of the ASIG algorithm,
patients involved in the derivation study [13] for this algorithm were excluded.
Definitions

Based on the current World Health Organization (WHO)
classification, in this study, patients were classified as nonPH or WHO group 1 PH (PAH), WHO group 2 PH (left
heart disease-associated PH), or WHO group 3 PH (lung
disease/hypoxia-associated PH). PH was defined as a mean
pulmonary artery pressure (mPAP) of at least 25 mm Hg
on RHC at rest; therefore, non-PH was defined as mPAP
of less than 25 mm Hg. PAH was defined as mPAP of at
least 25 mm Hg at rest and pulmonary capillary wedge
pressure (PCWP) of not more than 15 mm Hg with no
more than mild ILD on HRCT and an FVC of more than
60% predicted. WHO group 2 PH was defined as mPAP of
at least 25 mm Hg at rest and PCWP of more than
15 mm Hg. WHO group 3 PH was defined as mPAP of at
least 25 mm Hg at rest and PCWP of not more than
15 mm Hg with FVC of less than 70% predicted plus
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moderate or severe ILD on HRCT [5,14]. Patients with
PH underwent CT pulmonary angiography or V/Q imaging to exclude chronic thrombo-embolic PH (WHO
group 4 PH).
Screening algorithms

As described above, the DETECT screening algorithm
(Figure 1) includes eight variables and a two-step
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decision tree. At ‘step 1’, risk points for each of the six
non-echocardiographic variables (FVC/DLCO, telangiectasia, anti-centromere antibody (ACA), NT-proBNP,
urate, and ECG right axis deviation) are calculated by
using nomograms as presented in the article and verified
by using a customized calculator sourced from a dedicated website [17]. These are added together to obtain
the ‘total step 1 risk points’. If the ‘total risk points from

Figure 1 Summary of screening algorithms. Ab, antibody; ASIG, Australian Scleroderma Interest Group; DLCO, diffusing capacity for carbon
monoxide; ESC/ERS, European Society of Cardiology/European Respiratory Society; FVC, forced vital capacity (percentage predicted);
HRCT, high-resolution computed tomography (chest); PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RA, right atrium; RHC, right
heart catheterization; SSc, systemic sclerosis; TR, tricuspid regurgitation; TRV, tricuspid regurgitant velocity; TTE, transthoracic echocardiography; WHO,
World Health Organization.
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step 1’ are more than 300, the patient is referred for TTE
and entered into ‘step 2’. At ‘step 2’, the risk points for the
two echocardiographic variables (RA area and TRV) are
calculated and added to obtain a total score for step 2. If
the ‘total risk points from step 2’ are more than 35, the
patient is referred to RHC. Overall, this means that a
positive screen for RHC referral in DETECT is a score of
300+ in ‘step 1’ together with a score of 35 or more in
‘step 2’ [14].
The ASIG screening algorithm (Figure 1) is composed of
two components: PFT (component A) and serum NTproBNP level (component B). Component A is present if
DLCO is less than 70% predicted with an FVC/DLCO of at
least 1.8, and component B is present if NT-proBNP is at
least 210 pg/mL. In this model, the screen is ‘positive’ if
component A, component B, or both components A and B
are present, and a screen is ‘negative’ if both component A
and component B are absent. All patients with a positive
screen move on to TTE together with further tests such as
HRCT, V/Q, and 6-minute walk test (6MWT) as clinically
indicated, mainly in order to exclude the other contributing factors for PH (left heart dysfunction, ILD, and pulmonary embolism). If no alternative explanation is found
for a positive screen, patients undergo confirmatory RHC
testing, regardless of sPAP at echocardiography [11].
A positive screen for RHC referral in the ESC/ERS
guidelines (Figure 1) is TRV of more than 3.4 m/s or
2.8 < TRV ≤ 3.4 m/s with symptoms (defined as at least one
of the following parameters: current dyspnea, current syncope/near syncope, presence of peripheral edema) or TRV
of not more than 2.8 m/s and above symptoms, together
with an additional suggestive echocardiographic variable
(defined as RA area of more than 18 cm2) [5].
In summary, TTE is a component of both the ESR/
ERS guidelines and the DETECT algorithm. In the former,
it is the sole investigation component; in the later, TTE
forms ‘step 2’ of the algorithm and is required if a patient’s
points from step 1 are greater than 300. TTE is not mandated in the ASIG algorithm, although it is recommended
in patients who screen positive, in order to obtain more information about cardiac valves and myocardial function.
Step 1 of the DETECT algorithm requires six variables:
three measured in blood tests (including NT-proBNP), one
determined by ECG (right axis deviation), one determined
by pulmonary function tests (FVC/DLCO ratio), and another determined by physical examination (telangiectasia).
In contrast, the ASIG algorithm is composed of two
tests—a single blood test for NT-proBNP and pulmonary
function tests—to determine DLCO percentage predicted
and the FVC/DLCO ratio.
Data collection

Data such as demographic and clinical variables and cardiac and pulmonary assessments were obtained from the
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ASCS database. All physical examination and investigation data were collected within 1 month of the first
RHC, before starting advanced PAH therapy. TTE was
performed according to standardized procedures only at
tertiary centers. Pulmonary involvement was assessed
by PFTs or HRCT or both. All DLCO values were reported as percentage predicted values and corrected for
hemoglobin [18]. All patients had serum collected for NTproBNP measurement within 1 month of their RHC and,
in cases of PAH, prior to the commencement of advanced
PAH therapy.
Statistical analysis

Data are presented as mean ± standard deviation for
continuous variables and as number (percentage or
proportion) for categorical variables. Normally distributed continuous variables were compared by using the
Student t test with unequal variances, whereas continuous non-parametric variables were compared by using
Kruskall-Wallis and Mann-Whitney U tests. The differences in frequency were determined by using chi-square
and Fisher’s exact tests. The predictive accuracy of the
algorithms is presented as sensitivity, specificity, PPV
and NPV, with 95% confidence intervals (CIs). An ‘alternate case scenario’ analysis (detailed in Additional file 1)
was also performed by assuming a prevalence for PAH
of 10%, the commonly accepted frequency of PAH in
SSc. A two-tailed P value of not more than 0.05 was
considered statistically significant. All statistical analyses
were performed by using STATA 13.0 (StataCorp LP,
College Station, TX, USA).

Results
Patient characteristics

Of 79 consecutive SSc patients with suspected PAH
undergoing RHC who fulfilled the inclusion criteria,
RHC revealed PH in 45 (57.0%) patients and PAH
(WHO group 1) in 29 (36.7%) patients. Among them, six
patients were excluded for the following reasons: three
because of FVC of less than 40% predicted and three because they had more than one missing variable in the
DETECT algorithm. Of the remaining 73 patients, in the
DETECT algorithm analysis, four patients were missing
RA area only, two patients were missing urate level only,
and 12 patients were missing ECG data. There were no
missing NT-proBNP data.
Among the 73 patients, PH was confirmed in 39
(53.4%) patients: 27 (36.9%) with PAH, 4 (5.5%) in the
WHO group 2 PH, and 8 (11.0%) in the WHO group 3
PH. Finally, 61 patients (27 PAH patients versus 34 nonPH patients) were included in the analyses of the performance of the algorithms for PAH. In three patients,
TRV was undetectable, and in these cases the ESC/ERS
guidelines could not be applied. Twenty-four patients
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had been included in the derivation study [13] for the
ASIG algorithm and were not used in the analysis of
the ASIG algorithm. WHO group 2 (n = 4) PH patients
were included in further performance analyses for PH.
WHO group 3 (n = 8) PH patients were included in
further performance analyses for precapillary PH and
PH (Figure 2).

ratio was significantly higher in the PAH group than in
the non-PH group. We did not find any difference in the
frequency of ECG right axis deviation between the two
groups, but significantly higher serum urate levels were
found in the PAH group (Tables 1 and 2).

Comparison between pulmonary arterial hypertension
and non-pulmonary hypertension groups

The sensitivity, specificity, PPV, and NPV of the DETECT
algorithm for PAH in this cohort were 100%, 35.3%, 55.1%,
and 100%, respectively. At the end of ‘step 1’, the median
(interquartile range) score of all 61 patients was 330.4
(315.1 to 340.5), and 53 patients would be referred for
TTE and proceed to ‘step 2’, so the referral rate for TTE
was 87%. In ‘step 2’, the median (interquartile range) score
of 53 included patients was 48.9 (37.2 to 55.3). Finally, 49
patients attained a score that would result in referral for
RHC, and the final referral rate was 80%. No PAH patient
was missed by the algorithm, but 22 patients who would
have been referred for RHC were found to have non-PH
on RHC. When the DETECT algorithm was used, 45% of
RHCs did not confirm a diagnosis of PAH.
Compared with the DETECT algorithm, the ASIG algorithm performed equally well in sensitivity (100%) and

Compared with non-PH patients, PAH patients were
older at the time of diagnosis of PAH, even though their
age at the onset of SSc was very similar. Unlike the sex
distribution of the DETECT study, in this cohort, patients with PAH were more likely to be female than patients without PH (93% versus 76%, P = 0.027). Similar
to previous reports, PAH patients were more likely to
have the limited subtype of SSc, to be ACA-positive, and
to have telangiectasia than non-PH patients. As expected, patients with PAH had a shorter 6-minute walk
distance (6MWD), lower DLCO level, higher NTproBNP level, larger RA area, and higher TRV than the
non-PH group. The FVC percentage predicted values
were similar between the two groups, but FVC/DLCO

Performance of DETECT, ESC/ERS, and ASIG screening
models for pulmonary arterial hypertension

79 SSc patients with suspected
PAH undergoing RHC
6 excluded (3 with FVC<40%, 3
with more than 1 missing variables)
73 SSc patients enrolled

39 PH patients (53.4%)

34 non-PH patients (46.6%)

27 patients with WHO
group 1 PH* (36.9%)

4 patients with WHO
group 2 PH** (5.5%)

8 patients with WHO
group 3 PH*** (11.0%)

All were involved in
validating the
performance of DETECT
algorithm for PAH
3 patients with
undetectable TRV were
excluded from validating
ESC/ERS guidelines

24 patients who have been
involved in the derivation
study for ASIG algorithm
were excluded from
validating ASIG
algorithm

Figure 2 Study cohort. *World Health Organization (WHO) group 1 pulmonary hypertension (PH) means pulmonary arterial hypertension (PAH).
**WHO group 2 PH means left heart disease-associated PH. This group was excluded for validating the performance of all models for PAH but
included in validating the performance for PH. ***WHO group 3 PH means lung disease/hypoxia-associated PH. This group was excluded
for validating the performance of all models for PAH but included in validating the performance for precapillary PH and PH. ASIG, Australian
Scleroderma Interest Group; ESC/ERS, European Society of Cardiology/European Respiratory Society; FVC, forced vital capacity (percentage
predicted); RHC, right heart catheterization; SSc, systemic sclerosis; TRV, tricuspid regurgitant velocity.
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Table 1 Comparison of the clinical characteristics of
pulmonary arterial hypertension and non-pulmonary
hypertension groups
Characteristics at the PAH
time of screening
(n = 27)

P value

Non-PH

Mean ± SD
or n (%)

Non-PH

(n = 34)

(n = 27)

(n = 34)

Mean ± SD
or n (%)

Mean ± SD
or n (%)

Mean ± SD
or n (%)

RA area, cm2

20.8 ± 6.6

17.6 ± 4.2

0.038

TRV, m/s

3.4 ± 0.6

2.7 ± 0.9

0.0002

sPAP, mm Hg

57.7 ± 19.6

41.6 ± 10.6

0.0004

3 (13)

3 (12)

0.073

48.6 ± 13.2

0.256

Age at study, years

66.8 ± 8.3

61.2 ± 11.9

0.033

Disease duration at
study, years

14.9 ± 12.6

12.8 ± 10.4

0.566

13.0 (3.2-21.9)b

10.3 (4.4-18.2)b

25 (93)

16 (76)

0.027

Limited

23 (85)

27 (79)

0.560

Diffuse

4 (15)

7 (21)

24 (89)

23 (68)

0.049

ANA

24 (89)

27 (90)

0.617

Anti-Scl70

1 (4)

3 (10)

0.373

Anti-cent

17 (63)

11 (32)

0.017

Investigations

TTE parameters

a

RAD on ECG
PFT results

SSc subtypes

Telangiectasia

1,619.6 ± 2,063.6

401.3 ± 689.4
b

<0.0001
b

841 (531.3-2,022.1)

143.6 (83.3-414.2)

Serum urate,
mg/100 mL

6.7 ± 2.2

5.6 ± 1.8

0.038

6MWD, m

310.4 ± 115.8

411.0 ± 114.2

0.003

a

Disease onset defined as the date of first non-Raynaud’s symptom. bMedian
(interquartile range). 6MWD, six-minute walk distance; ANA, anti-nuclear
antibody; anti-cent, anti-centromere antibody; anti-Scl70, anti-topoisomerase-1
antibody; NT-proBNP, N-terminal pro-B type natriuretic peptide; PAH, pulmonary
arterial hypertension; PH, pulmonary hypertension; SD, standard deviation; SSc,
systemic sclerosis.

NPV (100%), a little better in PPV (60%), and moderately
better in specificity (54.5%). The referral rate for RHC
was 68%, and the proportion of RHCs that did not confirm a diagnosis of PAH was 40%.
Compared with the other two algorithms, the ESC/
ERS guidelines had the lowest sensitivity, specificity, and
NPV, which were 96.3%, 32.3%, and 90.9%, respectively,
and similar PPV of 55.3%. One PAH patient was missed
and 47 patients would have been referred for RHC with
a referral rate of 81%. The proportion of RHCs that did
not confirm a diagnosis of PAH was 45%. The ‘missed’
PAH patient had a mildly increased pulmonary pressure
with mPAP of 26 mm Hg on RHC. Because of very mild
TR jet with TRV of 2.2 m/s and normal RA area of
14 cm2, this patient was missed by the ESC/ERS guidelines. This patient had telangiectasia, negative ACA antibody, normal NT-proBNP level of 73.7 pg/mL, no right
axis deviation on ECG, well-preserved WHO functional
class (WHO FC) of 2, and 6MWD of 467 m, but PFT
showed a very low DLCO predicted value of 44% and

FVC, % pred

91.6 ± 15.1

90.9 ± 25.6

0.900

DLCOb, % pred

47.9 ± 11.7

60.6 ± 14.9

0.0008

FVC/DLCO

2.0 ± 0.5

1.6 ± 0.4

0.0003

RHC results

Antibodies

NT-proBNP, pg/mL

P value

PAH

Age at disease onset, 52.9 ± 14.7
yearsa

Female

Table 2 Comparison of cardiac and pulmonary investigation
parameters in pulmonary arterial hypertension and
non-pulmonary hypertension groups

mPAP, mm Hg

36.4 ± 10.1

19.4 ± 3.4

<0.0001

mRAP, mm Hg

9.7 ± 3.9

5.5 ± 2.9

0.0001

PVR, Wood units

5.7 ± 3.3

1.9 ± 0.9

<0.0001

a

Right axis deviation (RAD) defined as QRS axis of at least 90°. bDiffusing
capacity for carbon monoxide (DLCO) values are reported as percentage
predicted values, corrected for hemoglobin. ECG, electrocardiogram; FVC,
forced vital capacity (percentage predicted); mPAP, mean pulmonary artery
pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension;
PFT, pulmonary function test; PH, pulmonary hypertension; pred, predictive
value; PVR, pulmonary vascular resistance; RA, right atrium; RHC, right heart
catheterization; SD, standard deviation; sPAP, systolic pulmonary artery; TRV,
tricuspid regurgitant velocity; TTE, transthoracic echocardiography.

high FVC/DLCO ratio of 2.27, with a normal FVC percentage predicted value of 100%. The performance characteristics of the three models for PAH are presented in
Table 3.
Alternate case scenario analysis for pulmonary arterial
hypertension

The prevalence of PAH in this cohort was 37%, which
was higher than the expected prevalence of 10% according to the commonly reported data in the literature [19].
This was because these patients had been selected on
the basis of the existing Australian guidelines summarized
above. So, assuming a prevalence of PAH of 10%, we performed an alternate case scenario analysis, using the point
estimates of sensitivity and specificity determined above.
The NPV of the models was unchanged, but as would be
expected, the PPV of all three models dropped significantly
below 20% (Table 3 and Additional file 1).
Differences in immunosuppressive therapy in
screen-positive and screen-negative patients

Use of immunosuppressive therapy (defined as any exposure irrespective of dose or duration) in the 12 months
immediately preceding the date of screening by patients

Hao et al. Arthritis Research & Therapy (2015) 17:7
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Table 3 Comparison of the performance of DETECT versus ESC/ERS versus ASIG screening models for pulmonary
arterial hypertension in patients with systemic sclerosis
PAH prevalence set at 10%a
DETECT

ESC/ERS

ASIG

DETECT

ESC/ERS

ASIG

n = 61

n = 58

n = 37

n = 61

n = 58

n = 37

Positive

49 (80.3)

48 (82.8)

25 (67.6)

Negativeb

12 (19.7)

10 (17.2)

12 (32.4)

True PAH on RHC

27 (44.3)

27 (46.55)

15 (40.54)

Sensitivity

100%

96.3%

100%

100%

96.3%

100%

(95% CI)

(87.2-100)

(81.0-99.9)

(78.2-100)

(54.1-100)

(54.1-100)

(39.8-100)

Specificity

35.3%

32.3%

54.5%

35.3%

32.3%

54.5%

(95% CI)

(19.7-53.5)

(16.7-51.4)

(32.2-75.6)

(23.8-50.4)

(15.6-41.0)

(33.5-69.2)

PPV

55.1%

55.3%

60%

14.7%

13.6%

19.6%

b

c

(95% CI)

(40.2-69.3)

(40.1-69.8)

(38.7-78.8)

(5.6-29.2)

(5.2-27.4)

(5.7-43.7)

NPV

100%

90.9%

100%

100%

98.7%

100%

(95% CI)

(63.1-100)

(58.7-99.8)

(73.5-100)

(83.2-100)

(76.8-100)

(80.5-100)

a

Refer to Additional file 1. bPositive or negative number screened by each of the algorithms. Values are presented as number (percentage). cTrue pulmonary
arterial hypertension (PAH) number confirmed by right heart catheterization (RHC). Values are presented as number (percentage). ASIG, Australian Scleroderma
Interest Group; CI, confidence interval; ESC/ERS, European Society of Cardiology/European Respiratory Society; NPV, negative predictive value; PPV, positive
predictive value.

who screened positive and patients who screened negative according to each algorithm was compared. There
were no statistically significant differences in the use of
cyclophosphamide, methotrexate, or mycophenolate for
each algorithm, nor for azathioprine or corticosteroids
for the ESC/ERS and ASIG algorithms. Interestingly,
azathioprine and corticosteroids were used by more patients who screened positive than patients who screened
negative using the DETECT algorithm (1/49 versus 3/12,
P <0.0001 for azathioprine; 6/49 versus 7/12, P <0.0001
for corticosteroids), suggesting that these drugs may be
associated with one or more of the parameters in the
DETECT algorithm such as raised serum urate, although
the small number of patients on these medications prevents us from drawing definitive conclusions in this
regard.
Performance of DETECT, ESC/ERS, and ASIG screening
models for precapillary pulmonary hypertension and
pulmonary hypertension

The performance of these screening models for precapillary PH (WHO group 1 and 3 PH) and for all types of
PH patients (WHO group 1, 2, and 3 PH) was also evaluated. We did this because it could be argued that these
‘screening’ algorithms need to detect patients at high risk
of PH, regardless of etiology, which then can be further
elucidated with ‘diagnostic’ testing. For precapillary PH,
the ASIG algorithm performed best with respect to sensitivity (100%) and NPV (100%), without missing any
true positive patients. The sensitivity and NPV of the
DETECT algorithm decreased to 97.1% and 92.3%, with

one ILD-associated PH (WHO group 3 PH) patient
missed. ESC/ERS guidelines did not miss any extra patients except for the PAH patient as noted above. For
screening for all types of PH patients, the three models
performed equally in sensitivity and NPV. The DETECT
algorithm missed one WHO group 3 patient, the ASIG
algorithm missed one WHO group 2 patient, and the
ESC/ERS guidelines missed one WHO group 1 patient.
The specificities of these three models for screening for
precapillary PH and PH were very similar to those seen
in screening for PAH, and the PPVs increased slightly.
The ASIG algorithm still performed the best with respect to specificity and PPV (Table 4).

Discussion
The DETECT algorithm is a novel evidence-based
screening model for PAH in patients with SSc and was
developed from a worldwide multi-center cross-sectional
study. This algorithm was verified in the derivation cohort to have high sensitivity and NPV [14], which are
thought to be the most important properties for evaluating a screening algorithm. The present study is the first
to evaluate the performance of the DETECT algorithm
among patients who were not included in the derivation
study. In our study, DETECT performed well, with sensitivity and NPV of 100%. No PAH patients were missed
by this algorithm in this cohort. Compared with ESC/
ERS guidelines, the DETECT algorithm involves more
variables and does not rely just on symptoms and TRV;
therefore, it can be used even in patients with undetectable TRV. The eight variables included in the final
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Table 4 Comparison of the performance of DETECT versus ESC/ERS versus ASIG screening models for precapillary
pulmonary hypertension and pulmonary hypertension in patients with systemic sclerosis
Precapillary PHa versus non-PH

PHb versus non-PH

DETECT

ESC/ERS

ASIG

DETECT

ESC/ERS

ASIG

n = 69

n = 66

n = 42

n = 73

n = 70

n = 46

Positivec

56 (81.2)

57 (86.4)

30 (71.4)

60 (82.2)

61 (87.1)

33 (71.7)

Negativec

13 (18.8)

9 (13.6)

12 (28.6)

13 (17.8)

9 (12.9)

13 (28.3)

d

True PAH On RHC

35 (50.7)

35 (53.0)

20 (47.6)

39 (53.4)

39 (55.7)

24 (52.2)

Sensitivity

97.1%

97.1%

100%

97.4%

97.4%

95.8%

(95% CI)

(85.1-99.9)

(85.1-99.9)

(83.2-100)

(86.5-99.9)

(86.5-99.9)

(78.9-99.9)

Specificity

35.3%

25.8%

54.5%

35.3%

25.8%

54.5%

(95% CI)

(19.7-53.5)

(11.9-44.6)

(32.2-75.6)

(19.7-53.5)

(11.9-44.6)

(32.2-75.6)

PPV

60.7%

59.6%

66.7%

63.3%

62.3%

69.7%

(95% CI)

(46.8-73.5)

(45.8-72.4)

(47.2-82.7)

(49.9-75.4)

(49.0-74.4)

(51.3-84.4)

NPV

92.3%

88.9%

100%

92.3%

88.9%

92.3%

(95% CI)

(64.0-99.8)

(51.8-99.7)

(73.5-100)

(64.0-99.8)

(51.8-99.7)

(64.0-99.8)

a

Precapillary pulmonary hypertension (PH) means World Health Organization (WHO) group 1 (PAH) and 3 (lung disease/hypoxia-associated) PH. bPH means WHO
1, 2 (left heart disease-associated), and 3 PH. cPositive or negative number screened by each of the algorithms. Values are presented as number (percentage).
d
True PAH number confirmed by right heart catheterization (RHC). Values are presented as number (percentage). ASIG, Australian Scleroderma Interest Group; CI,
confidence interval; ESC/ERS, European Society of Cardiology/European Respiratory Society; NPV, negative predictive value; PAH, pulmonary arterial hypertension;
PPV, positive predictive value.

DETECT algorithm were derived from univariable and
multivariable statistical analyses; some of these variables
have previously been verified as predictive factors for the
presence of SSc-PAH, such as FVC/DLCO [8-10], NTproBNP [11,12], telangiectasia [20], ACA [21,22], serum
urate [23,24], and TRV [2]. In our univariable comparison between PAH and non-PH groups, significant difference were found in seven of the eight variables. Right
axis deviation on ECG was not found to be different between these two groups. These results further verify the
plausibility of these selected variables. The variables in
the DETECT algorithm are easy to measure in clinical
practice. The nomogram in the original DETECT article
is easy to use for calculating the risk points, but the
process is time-consuming. The recently released calculator for this algorithm is easier and quicker to use than
the nomogram and can be accessed online [17].
It is important to note that the entry criteria for the
DETECT study were a DLCO of less than 60% and SSc
disease duration of more than 3 years. However, in clinical practice, these restrictions may miss some PAH patients who have either early SSc or a preserved DLCO.
Therefore, to assess the performance of DETECT in a
less selective group of patients, we did not apply these
entry criteria in the present study. In fact, in our study,
6.5% of PAH patients (n = 4) had DLCO greater than
60% and 8.2% of PAH patients (n = 5) had disease duration of less than 3 years. If we had applied these entry
criteria of the original DETECT study, we would have
missed these patients. Hence, our study has shown that

the DETECT algorithm may be reliably applied to patients
with DLCO of more than 60% and disease duration of less
than 3 years.
The ASIG algorithm was published shortly before
DETECT, and the higher specificity (54.5%), NPV (92.3%),
and PPV (61.5%) compared with the ESC/ERS guidelines
have been verified by a recent validation study [13]. In the
present study, we compared the performance of ASIG and
DETECT and found that, compared with the DETECT algorithm, the ASIG algorithm performed equally well with
respect to sensitivity and NPV. The ASIG algorithm reduced the referral rate for RHC by 12% compared with
the DETECT algorithm but did not increase the number
of ‘missed’ cases. Thus, it may be possible to rationalize
the use of this invasive procedure. In the ASIG algorithm,
only two tests are required, which makes clinical assessment easier and more economical.
Compared with the other two algorithms, ESC/ERS
guidelines had lower sensitivity and NPV. One PAH patient was missed by the algorithm because of very mild
TRV and normal right heart size. However, this patient
had some indicators of PAH (for example, an extremely
low DLCO percentage predicted and high FVC/DLCO
ratio), which may be the reasons why this patient was
not missed by the DETECT and ASIG algorithms. It
must also be noted that the ESC/ERS guidelines could
not be applied to three patients in whom there was no
TR jet on TTE.
At present, in clinical practice, the ESC/ERS guidelines
rely mainly on TTE but are still the main screening tool
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for PAH. Furthermore, doctors are familiar with TTE
and often judge the likelihood of PAH through measurement of TRV only. However, TRV cannot be obtained in
20% to 39% of patients [6,7]. In our cohort, if TRV were
used as a single assessment tool, 4% of PAH patients
would be missed when using a PAH suspicion threshold
of at least 2.8 m/s, and 48% would be missed when using
a threshold of more than 3.4 m/s.
In clinical practice, in addition to WHO group 1 PAH,
WHO groups 2 and 3 PH occur in patients with SSc
[25,26]. According to data from the North American
PHAROS (Pulmonary Hypertension Assessment and
Recognition of Outcomes in Scleroderma) study, WHO
groups 2 and 3 PH account for 10% and 21%, respectively, of all types of PH in patients with SSc [26]. The
symptoms in patients with WHO groups 2 and 3 PH are
similar to those of patients with WHO group 1 PAH,
and the prognosis of these patients may be even worse
than that of the group 1 patients. Two studies from UK
and France both showed the prognosis of SSc patients
with respiratory disease-associated PH (WHO group 3)
was significantly worse than the prognosis of patients
with isolated SSc-PAH (WHO group 1) [21,27]. This
suggests that it may be important to identify all types of
PH as early as possible. For this reason, although the
DETECT and ASIG algorithms were derived in patients
with WHO group 1 PAH, their performance in screening for WHO groups 2 and 3 PH was also assessed in
the present study. The DETECT algorithm missed one
WHO group 3 PH patient, and the ASIG algorithm
missed one WHO group 2 PH, but generally both algorithms were still effective in detecting these types of PH.
Of course, the small case number in these two groups
limits the interpretation of the findings. According to
the original article, if applied to the total SSc PH population, the DETECT algorithm could miss as many as 19%
of WHO group 2 PH patients and 37% of WHO group 3
PH patients [14].
Despite the limitations of the three screening algorithms we evaluated, they each performed reasonably
well in detecting SSc-PAH, echoing the sentiments of
many experts that any reasonable screening algorithm
applied for the early detection of SSc-PAH is better than
usual care. That said, accuracy, accessibility, and economic considerations are likely to influence the choice
of algorithm for SSc-PAH screening.
This study has some limitations. Firstly, the patients in
this study were a population enriched for PAH, although
this was also the case for the DETECT and ASIG derivation studies. Therefore, the prevalence of PAH was significantly higher than the expected prevalence of 10% in
an unselected SSc population, as reported in the literature [19]. Our alternate case scenario analysis showed
that in the case where the prevalence was set at 10%, the

Page 9 of 11

PPVs decreased significantly to lower than 20%, although
the NPVs were still very high. Owing to ethical considerations, it is difficult to perform an RHC in all patients
with SSc, especially those who are at very low risk of
having PAH.
Secondly, as this was a retrospective study, the ability
to avoid missed data is limited, so some patients with
more than one missing variable were excluded from the
analyses. Another limitation is the small case numbers,
especially for validating the performance of the ASIG algorithm, as patients involved in the original derivation
study for the ASIG algorithm were excluded. Furthermore, although the patients to whom the three screening
algorithms were applied in the current study were not
included in the original ASIG algorithm derivation study,
they were still recruited from the same source. This may
have enhanced the performance of the ASIG algorithm in
this setting. Accordingly, the findings should be confirmed
in a larger external group of patients. The impact of concomitant immunosuppressive therapy on results of screening with each of the algorithms also requires evaluation in
future studies. Finally, patients with severe ILD were excluded from this study. The performance of screening algorithms such as DETECT and ASIG in the setting of
coexistent ILD merits further evaluation.

Conclusions
In summary, the DETECT and ASIG algorithms outperform the ESC/ERS guidelines, with a high sensitivity,
which is the most important feature for a screening algorithm, reducing or eliminating missed diagnoses. The
ESC/ERS guidelines have limitations in patients with undetected or mild TR jet. The specificity of all of the
screening models is low, as may be expected, but the
ASIG algorithm performed better with respect to specificity and reduced the number of referrals for RHC. Ultimately, it is likely that the choice of SSc-PAH screening
algorithm will also depend on cost and ease of application.
Additional file
Additional file 1: Details of the ‘alternate case scenario analysis’.
Description: Alternate case scenario analysis assuming pulmonary arterial
hypertension (PAH) prevalence of 10%.
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